Trinity Life Sciences developed an AI algorithm to improve portfolio decision-making by predicting commercial success of drug launches. Using data from 250+ U.S. launches since 2014 and 20+ variables on product, indication, competition, and company factors, the model achieved over 90% accuracy in forecasting 5-year revenues, far surpassing analyst consensus at under 60%. Product efficacy, safety, and convenience emerged as top predictors, followed by unmet need and innovation. The tool helps pharma companies identify high-potential assets, optimize investment, and refine clinical and commercialization strategies.

Join for free to read